Investing.com -- Cosmo Pharmaceuticals ’ shares jumped more than 20% on Wednesday after the Swiss drugmaker reported that two Phase III trials of its hair-loss treatment Breezula met their co-primary ...
* Preliminary analysis of the data indicates that the study met both its two pre-defined co-primary efficacy endpoints Source text for Eikon: Further company coverage: ...
April 16 (Reuters) - Cassiopea SpA: * CASSIOPEA ANNOUNCES VERY POSITIVE PHASE II TWELVE MONTHS RESULTS FOR BREEZULA® (CLASCOTERONE) IN TREATING ANDROGENETIC ALOPECIA Get a look at the day ahead in ...
Cosmo has identified Breezula as one of its key programs, and the note said the update “offers a clear step forward for the equity story,” with the 12-month readout labeled the final major element ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results